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Abstract
Background: Traumatic injuries are physical insults to the body that are prevalent worldwide. Many individuals
involved in accidents suffer injuries affecting a number of extremities and organs, otherwise known as multitrauma
or polytrauma. Traumatic brain injury is one of the most serious forms of the trauma-induced injuries and is a
leading cause of death and long-term disability. Despite over dozens of phase III clinical trials, there are currently no
specific treatments known to improve traumatic brain injury outcomes. These failures are in part due to our still
poor understanding of the heterogeneous and evolving pathophysiology of traumatic brain injury and how factors
such as concomitant extracranial injuries can impact these processes.
Main body: Here, we review the available clinical and pre-clinical studies that have investigated the possible
impact of concomitant injuries on traumatic brain injury pathobiology and outcomes. We then list the
pathophysiological processes that may interact and affect outcomes and discuss promising areas for future
research. Taken together, many of the clinical multitrauma/polytrauma studies discussed in this review suggest that
concomitant peripheral injuries may increase the risk of mortality and functional deficits following traumatic brain
injury, particularly when severe extracranial injuries are combined with mild to moderate brain injury. In addition,
recent animal studies have provided strong evidence that concomitant injuries may increase both peripheral and
central inflammatory responses and that structural and functional deficits associated with traumatic brain injury may
be exacerbated in multiply injured animals.
Conclusions: The findings of this review suggest that concomitant extracranial injuries are capable of modifying
the outcomes and pathobiology of traumatic brain injury, in particular neuroinflammation. Though additional
studies are needed to further identify the factors and mechanisms involved in central and peripheral injury
interactions following multitrauma and polytrauma, concomitant injuries should be recognized and accounted for
in future pre-clinical and clinical traumatic brain injury studies.
Keywords: Multitrauma, Polytrauma, Traumatic brain injury, Inflammation, Concussion, Animal model, Clinical,
Cytokines, Bone fracture
Background
Traumatic injuries caused by physical insults to the body
are a common and serious medical problem. Because of
the high-impact nature of trauma-inducing accidents, pa-
tients commonly suffer concomitant injuries to multiple
body regions and organs, otherwise known as multitrauma
or polytrauma. Amongst the most devastating of trauma
injuries, traumatic brain injury (TBI) is a leading cause of
death and morbidity worldwide. To date, there is still no
treatment known to improve TBI outcomes, which is in
large part due to our poor understanding of its evolving
pathophysiology, and how factors such as concomitant
peripheral injuries can impact these processes. In light of
the ongoing failures in clinical trials in TBI, and the heavy
burden of TBI on society, factors like concomitant extra-
cranial injuries must be acknowledged and studied as we
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strive to improve the outcome of TBI patients. Here, we
review the available clinical and pre-clinical studies that
have investigated the possible impact of concomitant in-
juries on TBI pathobiology and outcomes, summarize the
potential interactive pathophysiologies with a particular
focus on neuroinflammation, and discuss potential areas
for future research.
Traumatic injuries
Traumatic injuries are physical insults to the body of
sudden onset that are induced by mechanical forces and
commonly occur in motor vehicle accidents, slips and
falls, sports activities, industrial accidents, assaults, and
the warzone [1–6]. Trauma injuries accounted for 5.8
million deaths globally in 1998, and this number is esti-
mated to increase to 8.4 million annual deaths by 2020
[7]. In the USA, each year, approximately 30 million in-
dividuals are hospitalised from injuries sustained from
motor vehicle accidents, slips and falls, or being struck
by/against an object, with the estimated lifetime medical
costs associated with these injuries thought to be over
$50 billion [8]. Traumatic injuries are commonly classi-
fied and quantified using the Abbreviated Injury Scale
(AIS) [9]. The AIS is an anatomical-based trauma scor-
ing system that is used to evaluate and rank injuries on
a numerical scale ranging from 1 (mild; e.g. superficial
laceration) to 6 (fatal injuries) in nine independent body
regions, i.e. the head, face, neck, thorax, abdomen, spine,
upper extremity, lower extremity, and external regions
[9]. Of particular relevance to TBI, the Glasgow Coma
Scale (GCS) is the universally accepted severity classifi-
cation system for TBI. The GCS is comprised of three
component tests involving the Eyes, Motor, and Verbal
scales. The Eyes scale ranges from 1 (no response) to 4
(spontaneous). The Motor scale ranges from 1 (no re-
sponse) to 6 (obeys commands), and the Verbal scale
ranges from 1 (no response) to 5 (oriented and con-
verses normally). The summation of these scales allows
for a total GCS score ranging from 3 to 15. Based on
these scores, the GCS classifies TBI cases as mild (GCS
14–15), moderate (GCS 9–13), or severe (GCS 3–8).
Multitrauma and polytrauma
Due to the high-impact nature of trauma-inducing acci-
dents, it is common for patients to suffer injuries to
multiple body regions [5, 6]. The simultaneous traumatic
injury to multiple body regions has traditionally been la-
belled as multitrauma or polytrauma, with the terms be-
ing used interchangeably. However, in recent years,
there have been significant efforts to establish an inter-
national consensus regarding the specific definitions of
polytrauma and multitrauma. In 2014, an expert panel
proposed that the term polytrauma be applied when
there are two injuries that are AIS ≥ 3 and one or more
additional diagnoses (pathologic condition), that is,
hypotension (systolic blood pressure ≤90 mmHg,), un-
consciousness (GCS score ≤8), acidosis (base deficit
≤−6.0), coagulopathy (partial thromboplastin time ≥40 s
or international normalized ratio ≥1.4), and age
(≥70 years) [10]. Alternatively, it has been proposed that
Fig. 1 Possible pathways through which extracranial injury may alter TBI pathobiology. Secondary injury processes of TBI include
neuroinflammation, excitotoxicity, metabolic disturbances, apoptosis, ischemia, oxidative stress, and BBB disruption. The neuroinflammatory
response of TBI is characterized by microglial and astrocyte activation, leukocyte infiltration and elevated levels of pro-inflammatory cytokines. For
multitrauma/polytrauma patients, there is potential for the systemic effects of significant extracranial injuries to impact upon secondary injury
pathways of TBI, and in particular the neuroinflammatory response. Possible extracranial trauma-induced influences on TBI include elevated circulating
inflammatory cytokines, growth factors, reactive oxygen species, and for the patient with bone fracture, potential influence of fat emboli and mobilized
mesenchymal stem cells. Polytrauma may produce the added risk of central influences of sepsis, SIRS and hemorrhagic shock
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multitrauma be defined as injury to more than one body
region (not exceeding AIS ≥ 3 in two regions) without
systemic inflammatory response syndrome (SIRS) [11].
Because these are relatively new definitions, they have
not yet been adopted worldwide, and previous studies in
the field often use vague and inconsistent terminology.
Therefore, in this review, the term polytrauma will only
be applied when the specific criteria defined above by
Pape and colleagues [10] is clearly met, whereas multi-
trauma will be more broadly defined as traumatic injury
to multiple body regions (which may or may not encom-
pass polytrauma).
According to the Trauma Audit and Research Network
(TARN) database, multitrauma involving significant head
injury results in the highest risk of mortality amongst all
multitrauma patients and of all head injury patients,
around one third are deemed to have suffered multi-
trauma [12]. Importantly, the occurrence of multitrauma
often creates significant challenges for medical profes-
sionals when compared with monotrauma (i.e., injury to
one body region), largely due to the potential for com-
bined and interactive pathophysiologies between differ-
ent organ systems. [11] In particular, the multitrauma
patient with TBI may be at greater risk of suffering ad-
verse effects of such combined and/or interactive pro-
cesses, particularly given isolated TBI itself is a
condition with an inherent complex pathophysiology
and high risk for disability or mortality [13]. Herein, we
review the literature on multitrauma involving TBI with
concomitant peripheral injuries, with a particular focus
on how extracranial injuries may affect TBI pathobiology
and outcome.
Traumatic brain injury
TBI induced by mechanical forces is a spectrum disorder
currently classified as mild (e.g., concussion), moderate,
and severe. It is estimated that over 10 million people
suffer from TBI each year worldwide [14], and compared
to other types of traumatic injuries, it is the most com-
mon to result in death or disabilities [15, 16]. In the
USA alone, approximately 1.7 million people sustain a
TBI annually, with nearly 80 % treated in emergency,
16 % hospitalised, and 3 % resulting in death [17]. Those
who survive the initial TBI insult are often left with
long-term neurological deficits and a general decrease in
quality of life. Outcomes from TBI can be temporary or
permanent dysfunction of cognition, motor function,
physiology, and psychology [13] and post-TBI neuro-
logical disorders, such as chronic traumatic encephalop-
athy (CTE), dementia, and posttraumatic epilepsy [18,
19]. All of the abovementioned factors contribute to the
large economic burden of TBI, with direct costs per TBI
case approximately range from $25,000 to $114,000 ac-
cording to studies in the USA [14].
Brain damage occurring in TBI results from either pri-
mary or secondary injury mechanisms. Primary injury
involves tissue damage caused directly by mechanical
forces at the moment of impact and may include blood-
brain barrier disruption, necrosis, and axonal shearing
[13, 16, 20]. The primary injury alone can lead to intra-
cranial haemorrhage, cerebral oedema, and hydroceph-
alus [13, 16, 20]. The progressive brain damage is due to
a number of secondary injury processes including neuro-
inflammation, oxidative stress, apoptosis, metabolic ab-
normalities, proteopathies, and further injury to the
blood-brain barrier and axons [13, 16, 20]. Secondary in-
jury processes may occur within minutes to hours after
TBI [21–23] and, depending on the severity and con-
dition, may persist and progress into chronic neuro-
degeneration [13]. To date, however, the multifaceted
pathophysiology of TBI is not yet fully understood. Con-
sequently, all phase III clinical trials have failed and cur-
rently no treatment that is known to improve long-term
neurological outcomes in TBI patients. Importantly, all
of the drugs showed significant improvement in positive
outcomes in various pre-clinical TBI models, and all
pre-clinical trials used clean, monotrauma head injury
models. These translational failures may be in part due
to researchers and clinicians overlooking important and
common factors that may affect TBI pathobiology, such
as concomitant extracranial injuries.
Potential influence of peripheral injury on TBI
pathobiology and outcome
Blood-brain barrier disruption in TBI provides unprece-
dented access for peripheral factors to enter the normally
immune-privileged brain parenchyma. Several studies
have demonstrated the migration of peripheral leukocytes
into injured brain tissue following TBI [24–26]. However,
in multitrauma patients with TBI and concomitant extra-
cranial injury, the potential for peripheral involvement in
the pathobiology of TBI is substantially greater than for
patients with isolated TBI. For example, peripheral injuries
involving significant inflammatory responses may have the
potential to exacerbate the neuroinflammatory response
of TBI. The neuroinflammatory cascade in TBI is charac-
terized by the activation of the brain’s microglia and astro-
cytes, the release of inflammatory cytokines by neurons
and glia [27, 28]. Peripheral injuries such as bone fracture
can increase circulating levels of many of the inflamma-
tory cytokines that mediate TBI pathobiology [29–33];
therefore, the multi-injured patient may be at increased
risk of suffering from worsened TBI outcomes. In
addition, significant extracranial injuries have the potential
to induce other systemic changes, such as haemorrhagic
shock [34, 35], fat embolism [36, 37], and elevated levels
of reactive oxygen species [38] and growth factors
[29, 39, 40], all of which have the potential to influence
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the secondary injury process of TBI. However, despite the
high prevalence of multitrauma, and an increasing recog-
nition of potential interactions in injury pathologies, mul-
titrauma involving TBI remains poorly understood and is
under studied both in the experimental and clinical
settings [41]. Recently, however, several clinical and basic
investigations have emerged describing influences of per-
ipheral injuries on TBI pathobiology and outcomes, indi-
cating a greater appreciation of the complexities of
multitrauma may allow for more appropriate care in this
subset of TBI patients.
Clinical multitrauma/polytrauma investigations
Several clinical studies have investigated the effect of con-
comitant extracranial injuries on outcomes following TBI,
though the findings of these studies have been mixed.
While many have reported increases in patient mortality
[15, 42–45], worsened functional outcomes [43, 46, 47],
and other effects [27, 48, 49], some have concluded that
the presence of concomitant extracranial injury has little
to no influence on TBI outcome [50–52]. Because the vast
majority of clinical multitrauma and polytrauma studies
have been conducted retrospectively using trauma data-
bases, interpretations of these studies must be tempered
by the existence of several limitations and confounding
variables. Many of these variables are difficult to avoid in
the clinical setting, such as variations in injury locus and
mechanism and differences in treatments (pharmaco-
logical or surgical). Further confounding multitrauma and
polytrauma investigations is that the average age of multi-
injured patients is often significantly lower than for iso-
lated TBI patients ([43, 48, 51, 53], see Table 1—limita-
tions). There are linear relationships between increasing
age and both unfavourable outcomes and mortality in
adult TBI patients [54]. Consequently, the impact of mul-
titrauma or polytrauma on TBI outcomes may be masked
by improved outcomes related to the younger age of these
patients, particularly when compared to older isolated TBI
patients. Additionally, a significant limitation in the design
of many of these studies lies in the variable, often ambigu-
ous definition and separation of injury location and sever-
ity. Though many have utilized the conventional GCS and
AIS scores to define injury severity upon admission, most
fail to separate results based on extracranial injury loca-
tion and the various combinations of GCS and AIS scores.
Furthermore, these injury severity scales are highly object-
ive and do not account for mechanism of injury. Perhaps
the most significant factor limiting previous clinical inves-
tigations into the influence of peripheral injury on TBI
outcomes is the restricted nature of the assessed out-
comes, with nearly all studies conducted retrospectively
and therefore primarily analysing mortality rates and/
or Glasgow Outcome Scale (GOS) available in data-
bases such as the Corticosteroid Randomisation After
Significant Head Injury (CRASH) and International
Mission for Prognosis and Analysis of Clinical Trials
in TBI (IMPACT). Though these investigations fail to
reveal the specific influence peripheral injury may
have on the multifaceted neurological impairments as-
sociated with TBI, particularly given the GOS has
been criticized for its lack of sensitivity and may itself
be directly influenced by concomitant injuries, overall,
they do suggest a possible association between extra-
cranial injuries and worsened patient outcome post-
TBI (Table 1).
Patient mortality
The most widely studied outcome in clinical investiga-
tions of multitrauma/polytrauma with TBI is mortality
rate of patients surviving the early stage (first hours) of
injury. Several studies have provided evidence for poten-
tial synergistic effect of concomitant head and peripheral
injuries on mortality. The most comprehensive study to
date on the influence of concomitant extracranial injur-
ies on mortality rates in TBI patients is a meta-analysis
of the IMPACT, CRASH, and TARN databases con-
ducted by van Leeuwen and colleagues [45]. By compil-
ing a pooled, odds ratio adjusted for core prognostic
parameters (e.g. age, GCS motor score, pupil reactivity,
hypotension), this large-scale observational study pro-
vides strong evidence that a major extracranial injury
(AIS ≥ 3) increases mortality rates in TBI patients [45].
However, it is important to note that extracranial injur-
ies had less impact on outcomes of patients with severe
TBI (compared with that for mild and moderate TBI
patients).
This conclusion drawn from this meta-analysis is simi-
lar to that made by other large-scale trauma registry
studies, reporting significant effects of peripheral injury
on mortality in mild to moderate TBI, but not in severe
TBI. Genarelli and colleagues [15] found that mortality
following TBI was not influenced by extracranial injur-
ies, except when moderate head injuries (AIS 3–4) were
accompanied with very severe extracranial injuries (AIS
4–6) [15]. A recent Austrian study also reported similar
mortality rates between isolated TBI (AIS head <6) and
TBI plus concomitant peripheral injury (AIS > 2); how-
ever, for patients with a mild TBI (AIS head = 2), mortal-
ity rate was significantly higher in those also suffering
peripheral injury [43]. Another recent study used the
IMPACT prognostic model to assess the influence of ex-
tracranial injury on TBI and confirmed that concomitant
peripheral injury was associated with increased mortality
in patients with mild-moderate (GCS 9–13) but not with
severe TBI (GCS 3–8) [47]. Siegel and colleagues [44]
found mortality rate was considerably higher in patients
with extracranial injuries (AIS ≥ 3) and blunt TBI of all
severities (GCS 3–14); however, the most substantial
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Table 1 Clinical studies investigating the effect of extracranial injury (ECI) on traumatic brain injury (TBI)
Studies reporting effects of ECI on TBI
Author Subjects Major Relevant Findings Limitations
Kumar et al., 2015 114 TBI patients
TBI: GCS ≤ 8, AIS ≥ 3 and evidence of damage by CT
PT: TBI + AIS ≥ 3 at least one ECI
- Weekly average patient serum IL-6 and IL-10 higher in PT
compared to isolated TBI group
- No difference in GOS scores between TBI and PT patients
–TBI group older than PT (Mean age 39 v 30)
–PT group higher incidence of skull fractures
–Low numbers
Leitgeb et al., 2013 767 TBI patients
TBI: AIS 2–5 (Mean 4)
MT: TBI + AIS > 2 at least one ECI
–Mortality higher in mild TBI (AIS = 2) patients with ECI,
however overall mortality comparable between groups
–Favourable outcome (GOS 4/5) reported in more MT
patients
–TBI group older than MT (Mean age 61 v 46)
–Orthopaedic interventions common (25% MT
had ECI surgery) but not accounted for
Lingsma et al., 2013 508 TBI patients
TBI: GCS 9–13 (moderate), 3–8 (severe)
MT: TBI + ECI (Median ISS = 4)
–Unfavourable outcome (GOS = 2/3) and mortality higher
for patients with moderate TBI and ECI than for isolated
moderate TBI
–Missing patients in follow up
–Variability in ECI severity
Leong et al., 2013 100 TBI patients
TBI: mild (GCS 13–15), moderate (9–12), severe (3–8)
MT: TBI + AIS ≥ 3 at least one ECI
–Fewer mild TBI patients with ECI made ‘good recovery’
(GOS = 5) compared with those with isolated mTBI
–Low numbers
Van Leeuwen et al., 2012 39,274 TBI patients (IMPACT, CRASH, TARN databases)
TBI: GCS 13–15 (mild), 9–12 (moderate), 3–8 (severe)
MT: TBI + AIS ≥ 3 (or requiring hospital admission) at
least one ECI
–IMPACT/CRASH pooled adjusted OR: Effect of ECI on
mortality = 2.14 in mild-, 1.46 moderate-, 1.18 severe-TBI.
–TARN adjusted OR higher in MT patients (2.81 mild-,
2.18 moderate-, 2.14 severe-TBI).
–Missing values in databases
–Variability in ECI severity
–No functional outcomes
Lefering et al., 2008 21,356 trauma patients
Various combinations of TBI and/or ECI to extremity or
torso (AIS 0–6)
–Non-significant increase in mortality in MT versus TBI
only overall, but significant difference at all TBI severities
when ECI AIS ≥ 4
–No GCS used
–No functional outcomes
Hensler et al., 2002 125 trauma patients
TBI: GCS ≤ 8 or AIS ≥ 3
PT with TBI: TBI + AIS ≥ 3 for one ECI
PT without TBI: AIS ≥ 3 for two ECI
–Serum levels of IL-6, IL-10, 55- and 75-kDa soluble tumor
necrosis factor receptors, polymorphonuclear neutrophil
elastase all lower in patients with TBI only compared with
PT (with and without TBI)
–Low numbers
–TBI group older than PT (Mean age 42 v 36)
–Only pathological changes reported
Siegel et al., 1991 1709 TBI patients
TBI: GCS 13–14 (mild), 9–12 (moderate), 7–8 (moderately
severe), 4–6 (severe), 3 (near fatal)
MT: TBI + ECI separated by location (no defined AIS)
–Overall mortality rate (all GCS) almost tripled in blunt TBI
patients with pelvis or femur fracture (similar results for
lung-, liver-, bowel-, major vessel- injury).
–Increase in mortality most substantial in mild to
moderate TBI.
–Variability in ECI severity
–No functional outcomes
Gennarelli et al., 1989 16,524 TBI patients
TBI: AIS 2–6
MT: TBI + AIS 1–6 at least one ECI
–Synergistic effect on mortality when moderate head
injuries (AIS 3–4) combined with severe ECI (AIS 4–6).
–No additive effect on mortality when ECI AIS ≤ 3
–No GCS used
Studies reporting no/inconclusive effects of ECI on TBI
Author Subjects Major Relevant Findings Limitations
Stulemeijer et al., 2006 299 TBI patients
TBI: GCS 13–15
MT: TBI + AIS ≥ 2 for one ECI
–Mild TBI patients with ECI had worsened GOS-E scores,
however no differences in post-concussion symptoms
at 6 months
–Acute symptoms (headache, dizziness, nausea) lower
in MT group
–TBI slightly more severe in MT patients
–Symptoms masked by frequent use of
analgesic in MT patients?
Sarrafzadech et al., 2001 119 trauma patients
TBI: GCS 3–7, Mean total ISS = 25
MT: TBI + AIS other 1–6, Mean total ISS = 39.5
–No difference in physiological variables between patients
with isolated TBI or MT with TBI between days 1–12
post-injury
–TBI group older than MT (Mean age 36 v 28)
–Low numbers















Table 1 Clinical studies investigating the effect of extracranial injury (ECI) on traumatic brain injury (TBI) (Continued)
ECI only: AIS other 1–6, Mean ISS = 29 –No differences in GOS score at 6 and 12 months
between TBI and MT patients, higher GOS scores in
extracranial injury only patients.
Baltas et al., 1998 386 TBI patients
TBI: GCS 3–8
MT: TBI + ECI (no defined AIS)
–No difference in mortality in MT versus TBI only groups. –No defined AIS for extracranial injury
–No functional outcomes















Table 2 Animal studies on the effects of extracranial injury on TBI
Author Subjects Major Relevant Findings Limitations
Yang et al., 2016 Male C57BL/6 mice. 12–14 weeks old
Sham: Incisions etc., no trauma
TBI: CCI (open skull, 4.5 m/s, penetration depth 1 mm)
MT: TBI + FX (Tibia, intramedullary pin)
MT treated: TBI+ HMGB1 (10mg/kg 60 min prior to FX)
–Elevated brain levels of IL-6 at 2- and 4-days in MT mice
compared to TBI mice, higher levels of TNF-α and IL-1β
levels at 4 days.
–Brain lesion volume and edema elevated in MT mice
compared to TBI mice at 4 days
–MT mice pre-treated with HMGB1 had reduced neurological
scores, edema and brain lesion volumes at 2 and 4 days
–No FX only group: FX affect neurological scores?




Shultz et al., 2015 124 male C57BL/6 mice. 12 weeks old
Sham: Incisions etc., no trauma
TBI: Weight-drop (333 g rod, 2 cm drop)
FX: Tibia (intramedullary pin)
MT: TBI + FX
–Brain IL-1β levels higher in MT group compared to all
groups at 24 h and 35 days, GFAP elevated in MT mice
at 24 h and 35 days, neutrophil highest in MT mice at 24 h
–Edema and blood–brain barrier damage higher in MT
group compared to all groups at 24 h
–Lateral ventricle enlargement and diffusion abnormalities in
MT mice not found other groups at 35 days
–Altered anxiety-related behavior in MT mice compared to all
groups at 35 days
- Variability in serum cytokine levels
–No chronic time-point
Weckbach et al., 2013 Male C57BL/6 mice. 8–9 weeks old.
Sham: Incisions etc., no trauma
Blunt chest trauma (ChT): Blast wave to thorax
TBI: Weight-drop (333 g rod, 2 cm drop)
FX: Femur (intramedullary pin) with soft tissue injury
MT (3 groups): TBI + ChT or FX + ChT or TBI + FX
PT: TBI + ChT + FX
–Serum IL-6 higher in PT mice compared to all other groups
at 2 h, only elevated in PT and MT mice involving TBI at 6 h
–Serum G-CSF and CCL-2 higher in MT mice with TBI than for
TBI only mice
–Serum neutrophil apoptosis marker expression decreased
in PT animals only
–Only acute time-point analysis
–Systemic analysis only
Probst et al., 2012 45 male C57BL/6 mice. 8–10 weeks old.
TBI: Weight-drop (3m/s; weight details not included)
FX/Shock: Femur (wood splint) + 60% blood vol. loss
PT: TBI + FX/Shock
–Mortality rates higher in PT compared to FX/Shock and
TBI only
–Serum IL-6, TNF-α and CCL-2 higher in PT animals compared




Weckbach et al., 2012 352 male Wistar rats, 10–12 weeks old
Sham: Incisions etc., no trauma
Blunt chest trauma (ChT): Blast wave to thorax
TBI: Weight-drop (severity not disclosed)
FX: Tibia-fibula (fixation not disclosed) + soft tissue injury
MT (2 groups): TBI + ChT or ChT + FX
PT: TBI + ChT + FX
–Serum IL-6 singificantly increased in PT animals only
–Serum neutrophil chemoattractant expression elevated only
in multiply injured animals
–No changes in serum TNF-α
–Only acute time-point analysis
–No FX only group
–Variability in serum cytokine levels
–Systemic analysis only
Mirzayan et al., 2012 60 male C57BL/6 mice. 8–10 weeks old.
TBI: CCI (open skull, 3 m/s, penetration depth 1 mm)
FX/Shock: Femur (un-supported) + 60% blood vol. loss
PT: CCI + FX/Shock
–Trend (p = 0.068) towards elevated reactive astrocyte (GFAP)
density in the ipsilateral hippocampus of PT compared to TBI
only mice at 4 days
–No sham animals (only controls)-
–Single time-point analysis
Maegele et al., 2007 100 male Sprague–Dawley rats, 300–250g
Control: No trauma
TBI: LFP (2.1 atm)
FX: Tibia (un-supported)
MT: TBI + FX
–Serum IL-6 and IL-10 levels higher in MT rats compared
TBI only and FX only rats during first week post-injury
–No differences in serum tumour necrosis factor receptor
1 and IL-1β between groups
–Small numbers per group for plasma analysis (3–5)
–No sham animals (only controls)
–Systemic analysis only
–Confounding craniotomy















increase in mortality rate was observed in multitrauma pa-
tients with mild-moderate TBI (GCS 13–15, 9–12) [44]. A
study of severely head injured patients (GCS 3–8) found
no difference in mortality between isolated TBI and TBI
with extracranial injuries (no defined AIS), again suggest-
ing that additional injuries likely have little influence on
mortality following severe TBI [50]. Lefering et al. [42]
however found that extracranial injuries of AIS grade 4
and above significantly increased TBI mortality across a
whole range of TBI severities (AIS 1–6) [42].
The aforementioned clinical studies have several ca-
veats, including wide range of ages of patients enrolled
in the studies [43, 51], the use of different injury classifi-
cation schemes [15, 43, 47, 50], and the use of the infer-
ior AIS rather than GCS scores to classify TBI severity
[15, 42, 43]. Furthermore, the majority of the mortality-
focused multitrauma studies did not feature an extracra-
nial only (without TBI) group [43–45, 47, 50], and all
failed to report cause of death. These shortcomings
make it difficult to understand the effect of concomitant
injuries on TBI-related mortality. Despite these limita-
tions, taken together, these clinical findings provide
some evidence of a correlation between presence of con-
comitant extracranial injuries and increased risk of mor-
tality, particularly following mild-moderate TBI. Further
work is needed however to establish whether this pos-
sible increased risk of death is largely a direct conse-
quence of peripheral injury or the result of these injuries
potentiating TBI pathobiology.
Functional outcomes
Assessments of functional outcomes of multitrauma/
polytrauma patients with TBI are confined to a small
number of studies that have conducted basic functional
testing in the months following injury. Functional out-
comes findings of these studies are mixed, with recovery
predominately assessed using the GOS or GOS-Extended
(GOS-E). The GOS rates patient recovery on a five-
category scale, i.e. death, vegetative state, severe disability,
moderated disability, or good recovery. The GOS-E fur-
ther categorizes recovery into eight categories by subdivid-
ing categories of severe disability, moderated disability and
good recovery into a lower and upper category. Kumar et
al [53] found no difference in GOS scores at 6 months
post-injury between severe TBI (AIS head ≥3) and poly-
trauma patients (AIS head ≥3, GCS ≤ 8, AIS other > 3).
These findings were likely compromised by the increased
mean age of isolated TBI patients [53], with increased age
throughout adulthood associated with higher likelihood of
unfavourable outcome post-TBI [54]. This same age differ-
ence was also a likely confounding factor in the study by
Letigeb and co-workers [43], who surprisingly reported
favourable outcomes at 6 months in significantly more
multitrauma patients (AIS head 1–6, AIS other >2) than
patients with TBI only (AIS head 1–6). As with the previ-
ously discussed mortality data, it is tempting to speculate
on a possible correlation between TBI severity and the po-
tential for extracranial impact on functional recovery, as
some researchers have described worsened functional out-
comes in mild TBI patients. Recently, a study by Lingsma
et al. [47] reported that functional outcome (GOS-E) was
primarily affected by extracranial injuries following mild-
moderate (GCS 9–13) but not severe TBI (GCS 3–8). An-
other study on patients with mild-TBI (GCS 13–15) found
worsened GOS scores at 18 months post-injury in patients
with concomitant injuries (AIS ≥ 3) [46]. Similarly, a study
on patients with either mild-TBI (GCS 13–15) and mild-
TBI with extracranial injuries (AIS ≥ 2) found those with
additional injuries had worsened GOS-E scores at
6 months post-injury; however, they reported no differ-
ences in post-concussion symptoms at this time-point be-
tween groups [52]. Though further investigations are
essential, these studies do suggest that functional outcome
after TBI is also impacted by concomitant injuries.
The conclusions of these studies are not only limited
by the confounding variables discussed earlier but also
by the nature and timing of the functional assessments.
The GOS and GOS-E assessments are still the most
commonly used primary outcomes for assessing patient
recovery [55, 56]; however, the insensitivity and subject-
ive nature of these assessments are often criticized and
now recognized as a factor possibly contributing to the
failure of several TBI clinical trials [57, 58]. There is a
growing consensus that improved functional assess-
ments will require use of outcome measures that better
quantify, without subjectivity, the many aspects of defi-
cits associated with TBI, such as cognitive, sensory,
motor, and emotional function [57, 58]. Furthermore, in-
ferences on the effect of multitrauma/polytrauma on
TBI may be confounded by the likely direct effect of
major, persisting extracranial injuries have on GOS
scores. Finally, the conclusions of these studies are lim-
ited by the single, 6-month end-point chosen for nearly
all GOS assessments. Given TBI is a highly heteroge-
neous condition that often features chronic and progres-
sive neurodegeneration, development of longitudinal
studies with repeated functional assessments will enable
greater characterization of short- and long-term deficits
that may be associated with concomitant extracranial in-
juries and TBI.
Pathobiology
The injured brain is more susceptible to secondary in-
sults, such as ischemia [59], hypotension [60], sepsis
[61], seizures [62], or surgical interventions albeit very
few clinical studies have investigated the effect of these
insults on neuroinflammation and other pathobiological
process of TBI. The effect of extracranial injuries on TBI
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pathobiology and thus outcome is demonstrated by the
contentious issue of bone fracture fixation procedures in
TBI patients. Many clinics practice ‘damage control or-
thopaedics’ and delayed definitive fracture fixation to
minimize ‘secondary hits’ to the injured brain [37, 63, 64].
While these orthopaedic practices are hypothesized to de-
crease the risk of worsened brain injury outcome by redu-
cing the potential for both haemodynamic complications
and an exacerbated inflammatory response, it is still de-
bated whether these trauma practices improve outcome
for TBI patients and, indeed, that these ‘secondary hits’ ac-
tually influence TBI pathobiology [64].
The systemic effects of isolated TBI and general trauma
have been widely investigated and are beyond the scope of
this review (see Keel and Trentz 2000 for review [35]);
however, the findings of these trauma studies may have
important implications when considering the potential in-
fluence of extracranial injury on TBI. Of particular, rele-
vance here is the trauma-induced development of SIRS, a
condition in which the extensive inflammatory state often
leads to damage of non-injured organs, such as the lung,
liver, and kidney [35, 63, 65, 66]. Given TBI frequently fea-
tures extensive damage to the blood-brain barrier [67, 68],
the normally immune-privileged brain tissue becomes vul-
nerable to secondary insults from the periphery [69];
therefore, it could be speculated that polytrauma-induced
SIRS may also influence the brain parenchyma, poten-
tially exacerbating the neuroinflammatory response and
worsening brain injury. As with many aspects of clinical
research however, such mechanistic understandings are
difficult to clearly establish, particularly given the
already complex and variable nature of secondary brain
injury.
Trauma is strongly associated with SIRS development,
and multiple traumas are thought to increase risk of
SIRS [35], but surprisingly few clinical studies have char-
acterized the systemic effects of TBI combined with ex-
tracranial injury. Studies on patients with severe TBI
(GCS ≤ 8) found those that also had a major extracranial
injury (AIS ≥ 3) had significantly higher serum levels of
pro-inflammatory cytokine interleukin-6 (IL-6) during
the first week post-injury [48, 53]. Hergenroeder et al.
[70] demonstrated a correlation between serum IL-6 and
intracranial pressure was present in patients with iso-
lated severe TBI. However, this correlation was not seen
in multiply injured patients, with the authors suggesting
orthopaedic trauma-induced increases in serum IL-6 re-
duced the prognostic accuracy of serum IL-6 in predict-
ing intracranial pressure [70]. Interestingly, serum levels
of the anti-inflammatory cytokine interleukin-10 (IL-10)
are also elevated in patients with both severe TBI and
extracranial injury when compared with isolated TBI
only [48, 53], suggesting multitrauma may also feature
heightened expression of anti-inflammatory factors.
Other inflammatory cytokines such as interleukin-1β
(IL-1β), tumour necrosis factor-α (TNF-α), and gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF)
have been shown to be elevated in the systemic circulation
following peripheral injury (e.g. bone fracture) [29, 31–33,
71] as well as in TBI [27, 72, 73]. It is therefore likely that
multitrauma patients may too have elevated post-injury
serum levels of these cytokines, but to the best of our
knowledge, this has not been investigated. Given IL-1β,
TNF-α, and GM-CSF are implicated in TBI [27, 72, 74–
76], analysis of serum and cerebrospinal fluid (CSF) levels
of these cytokines may provide important insights in to
the pathobiology of TBI following multitrauma.
Serum levels of S-100B, the protein biomarker fre-
quently used in pre-clinical and also in clinical TBI stud-
ies [72], has also been measured in the serum of
multitrauma patients. S-100B can be of extracranial ori-
gin, potentially reducing its suitability as a serum bio-
marker for TBI severity. In an attempt to determine the
influence of extracranial injuries on S100B expression,
Savola and colleagues analysed serum of patients with
isolated TBI, isolated extracranial injuries, and combined
injuries [49]. This study found median serum levels of
S100B correlated with TBI severity (isolated mild TBI
0.15 μg/L, isolated moderate to severe TBI 0.94 μg/L).
While they found isolated large extracranial injuries
(e.g. large fractures) moderately increased serum levels
(0.35 μg/L), they also found that when combined with
brain injury, large extracranial injuries substantially in-
creased circulating S100B levels in both mild (0.93 μg/L)
and severe (4.01 μg/L) TBI patients [49]. The moderately
elevated expression of S100B for isolated large extracranial
injures led the authors to conclude S100B may not be a
suitable predictive marker for TBI in multitrauma patients
[49]. Nonetheless, the substantial increase in S100B levels
observed in patients with both injury types could be inter-
preted as possible evidence of peripheral and central injury
interactions or common pathomechanisms. Further investi-
gations are clearly necessary to support such speculation.
In summary, while clinical data is insufficient, particu-
larly on the influence of multitrauma on the secondary in-
jury process after TBI, the aforementioned serum data
provides preliminary evidence that multitrauma may lead
to systemic inflammatory changes that have the potential
to affect the neuroinflammatory response of TBI. Future
clinical studies with clearly defined, specific research ques-
tions (e.g. how does limb fracture alter inflammatory pro-
files of patients with mild TBI?) are required to unearth
the particular pathological consequences and possible
therapeutic implications for multiply injured patients.
Animal studies
Because clinical multitrauma and polytrauma are
highly heterogeneous conditions that can involve
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various combinations of body regions and injury sever-
ities, it is not possible to have a single animal model that
is representative of all multitrauma/polytrauma scenarios.
However, the criteria used to define clinical multitrauma
and polytrauma (described above), and clinical studies
identifying the most common trauma injury combinations
have provided some guidance for developing initial animal
models with a high degree of clinical relevance. Rodent
models of multitrauma/polytrauma featuring TBI have
been developed over the last 10 years, enabling insights
into the influence of multiple injuries on both the systemic
and central inflammatory response, as well as preliminary
analysis on the structural and functional TBI outcomes
(Table 2). Importantly, pre-clinical studies to date have in-
corporated the two most common forms of significant ex-
tracranial injury in TBI patients, namely TBI combined
with extremity fracture or TBI combined with thoracic
trauma [6]. Herein, we discuss the recent pre-clinical pro-
gress in both multitrauma and polytrauma studies involv-
ing TBI.
In the initial experimental multitrauma studies fea-
turing rats, TBI was induced by lateral fluid percussion
injury (LFP) immediately followed by a closed tibial frac-
ture [77, 78]. These preliminary studies found that circu-
lating levels of IL-6 and IL-10 were significantly elevated
in the first 24–48 h following injury in animals with
combined injury compared to isolated injury only. How-
ever, the non-stabilized tibial fracture impaired hind
limb function and thus compromised the assessment of
locomotor function between groups [77, 78]. Nonethe-
less, the use of this novel multitrauma model showed for
the first time that the systemic inflammatory response
might be heightened in animals with both TBI and sig-
nificant peripheral injury.
Intensified systemic inflammatory responses have since
been reported in a number of subsequent animal models
of combined TBI and peripheral injury. In a murine
polytrauma model featuring weight-drop TBI along with
femoral fracture followed immediately by haemorrhagic
shock, circulating levels of IL-6, TNF-α, and chemokine
CC ligand-2 (CCL-2) were substantially elevated at 4 days
post-injury in animals with combined injury compared
to isolated injuries only [79]. Increased systemic inflam-
mation was also reported in rats with combined TBI,
chest trauma, and tibial/fibular fracture, with circulating
IL-6 significantly elevated in polytraumatized animals
but not those with isolated injuries only at 4 h post-
injury [80]. A subsequent similar investigation in mice
found that animals with TBI, bone fracture, and chest
trauma had elevated serum levels of IL-6 compared to
all other groups at 2 h post-injury, and by 6 h post-
injury, IL-6 expression was only elevated in serum of
multiply injured animals involving TBI [81]. This same
study also found that compared to mice with TBI only,
those given TBI along with femoral fracture had in-
creased circulating levels of granulocyte colony-
stimulating factor (G-CSF) and those given a TBI and
chest trauma had elevated plasma CCL-2 concentrations
at 6 hours post-injury [81]. Furthermore, expression of
markers of neutrophil apoptosis at 2 and 6 h post-injury
were markedly decreased in animals with three injuries
(TBI, fracture, and chest injury), but not animals with
single or double injuries. Interestingly, many of the
aforementioned increases in systemic inflammation in
experimental multitrauma/polytrauma studies may not
simply be an additive effect of the combined injuries, as
levels of several circulating inflammatory markers appear
to be significantly elevated when compared to the sum-
mated responses for the isolated injuries. Taken together,
these basic trauma findings provide some evidence that
multiple traumas can alter the systemic immune-
inflammatory response post-injury. The potential for
such alterations to impact peripheral organs is beyond
the scope of this review; the remainder of this review
will discuss the preliminary animal-based evidence sug-
gesting a potential impact of peripheral trauma on the
pathological changes of the injured brain.
The potential for peripheral injury affecting TBI
outcomes is supported by a number of studies providing
evidence that peripheral immune factors can alter experi-
mental TBI pathology. A systemic injection of lipopolysac-
charide in rats with a cortical contusion injury was shown
to increase the injury site expression of inflammatory and
apoptosis markers compared to vehicle-treated rats with
TBI [82]. Furthermore, peripheral administration of IL-1β
in rats with moderate LFP was shown to significantly in-
crease structural and behavioural deficits compared to
vehicle-treated animals, possibly due to a heightened neu-
roinflammatory response in IL-1β treated rats [83]. In
addition, a recent study found treatment with an antibody
targeting leukocyte infiltration significantly reduced neu-
roinflammation and behavioural deficits in rats with severe
TBI [26], indicating the role of peripheral leukocytes in
TBI is likely significant.
Despite the evidence that peripheral injuries induced
increased systemic inflammatory responses in rodents
TBI studies, and the evidence that peripheral immune
factors influence TBI, until recently, no studies had com-
pared the secondary injury process (or pathology) of TBI
between animals with isolated brain injury and those
also with peripheral trauma. Preliminary evidence for al-
tered TBI pathobiology in experimental polytrauma
came from mouse model featuring controlled cortical
impact (CCI) combined with femoral fracture with
hemorrhagic shock, with the investigators reporting a
near significant trend towards elevated reactive astrocyte
density in the ipsilateral hippocampus of polytrauma
mice compared to CCI only mice at 4 days post-injury
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[84]. The neuroinflammatory response to multitrauma
was more extensively analysed in a mouse model featur-
ing weight-drop TBI (mild to moderate severity) and tib-
ial fracture [85]. In this study, mice with tibial fracture
had an increased and prolonged neuroinflammatory re-
sponse, evidenced by the elevated brain tissue concen-
trations of IL-1β and glial fibrillary acidic protein
(GFAP; an indicator of astrogliosis) at 24 h and 35 days
post-injury, as well as elevated neutrophil expression,
edema, and blood-brain barrier disruption at 24 h post-
injury [85]. Furthermore, at 35 days post-injury, mag-
netic resonance imaging (MRI) showed that multitrauma
mice had enlarged ventricles and diffusion abnormalities
not seen in mice with isolated TBI, and behavioural test-
ing revealed changes in anxiety-related behaviours in
multitrauma mice only. Taken together, the findings
demonstrated for the first time that concurrent bone
fracture and brain injury can exacerbate structural and
behavioural deficits, possibly due to a heightened and
prolonged neuroinflammatory response compared with
isolated TBI only [85].
An exacerbated neuroinflammatory response to multi-
trauma was also found in a subsequent study on mice
exposed to CCI and tibial fracture [86]. In this model,
Yang and colleagues [86] found that when compared to
mice with TBI only, mice with TBI and bone fracture
had increased brain tissue IL-1β, TNFα, and IL-6 at
4 days post-injury [86]. Furthermore, multitrauma mice
also had increased edema and brain lesion volumes com-
pared to mice with TBI only. Neurological severity
scores were elevated in multitrauma mice compared to
TBI only mice at 4 days post-injury; however, given this
study lacked a fracture-only group, it is impossible to
rule out the contribution of bone fracture to this finding.
Finally, when the authors injected antibodies to the in-
flammatory mediator high mobility group 1 (HMGB1) at
60 min prior to fracture, they found that compared with
untreated multitrauma mice, those treated with neutral-
izing antibodies to HMGB1 had reduced neurological se-
verity scores and reduced brain damage at 24 and 48 h
post-injury. Similar findings were also recently described
in a murine model of stroke combined with bone frac-
ture, with mice undergoing bone fracture 24 h after is-
chemic injury found to have a significantly heightened
neuroinflammatory response that was prevented with
HMGB1 antibody treatment [87, 88].
The last decade has seen a substantial increase in the
number of animal-based studies of multitrauma, resulting
in growing body of evidence supporting the hypothesis
that multiple injuries may have pathological consequences
not seen with isolated injuries. In particular, several
studies have demonstrated that concomitant TBI and
limb fracture can produce significantly elevations in
circulating pro-inflammatory cytokines, with recent
findings also suggesting bone fracture may exacerbate the
neuroinflammatory response and worsen structural and
functional deficits following TBI. Additional studies are
however required, both to further characterize the patho-
biological consequences of TBI combined with bone
fracture and to investigate the possible central influ-
ence of other injuries most frequently combined with
TBI (i.e. thoracic and/or abdominal injury). When
choosing or developing animal models of multitrauma
or polytrauma, it is important that researchers place
priority on replicating the fundamental clinical char-
acteristics of these conditions, while minimizing the
presence of potentially confounding variables. With
regard to TBI, it is essential that surgery duration is
minimized in order to ensure multiple injuries are
able to be delivered in short succession if not simul-
taneously and to reduce the impact of potentially
confounding anaesthesia. In addition, TBI models in-
volving craniotomy (e.g. traditional CCI and fluid per-
cussion injury), a form of bone injury, may also represent
a confounding variable. For these reasons, TBI delivered
via closed-skull methods such as closed-skull CCI or
weight-drop injury, blast injury, or acceleration/deceler-
ation models may avoid confounding craniotomy while
still providing high clinical relevance. For investigations
into the polytrauma condition, it is recommended that re-
searchers clearly distinguish their model from multi-
trauma by ensuring it meets the specific criteria outlined
for this condition, i.e. presence of two significant injuries
(equivalent AIS ≥ 3) along with one or more additional
pathological diagnosis (e.g. hemorrhagic shock) [11].
Another factor to consider in attempting to recapitulate
clinical trauma is the timing of surgical procedures, with
the possible influence of delayed fracture fixation (often
performed clinically) on neuroinflammatory profiles and
TBI outcomes able to be quantified using animal models.
Taken together, animal models of multitrauma and poly-
trauma should be as representative of the most common
features of their clinical counterparts as possible, while
still permitting the use of reproducible injuries with min-
imal presence of confounds. Ultimately, an important
question that must be addressed is the generalizability of
findings based on common multitrauma and polytrauma
combinations to the broader spectrum of these conditions.
This is yet another topic that highlights the utility of ani-
mal models given the ability to compare different combi-
nations of trauma in highly controlled conditions.
Future directions
This review has highlighted several lines of evidence sug-
gesting a highly likely influence of extracranial injury on
TBI. Nonetheless, despite the recent progress in the area,
several significant limitations in the aforementioned stud-
ies have prevented the development of a greater
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understanding of central and peripheral injury interactions
following multitrauma, particularly in the clinical setting.
Though clinical trauma presents inevitable challenges and
several potentially confounding variables, such as hetero-
geneity of injuries, differences in patient demographics
(e.g. age, gender, ethnicity, genetic variances, medical his-
tory), and variations in clinical management (e.g. pharma-
cological and surgical interventions), clinical advances in
this area will require greater efforts to implement robust
study designs that either control or account for these vari-
ables. Furthermore, significant strides in our understand-
ing of TBI in multitrauma/polytrauma patients will
require incorporation of clinically relevant outcome mea-
sures, such as the various neuroimaging capabilities pro-
vided by MRI and positron emission tomography (PET).
These methods would allow for in vivo monitoring of
brain damage and neuroinflammation in isolated TBI ver-
sus TBI patients with extracranial injury [89, 90]. Add-
itionally, nearly all of the clinical investigations to date are
limited to single time-point outcome analysis, and given
the complex and dynamic nature of TBI pathologies, it is
important that future studies consider use of serial longi-
tudinal assessments of various structural and functional
outcomes.
Though inflammation seems a likely mechanism of in-
jury interaction in multiply injured patients, to date, no
studies have created inflammatory profiles of patients
with various combinations and severities of head and
peripheral injury. Such characterization will allow re-
searchers to determine not only if inflammation is
heightened in multiply injured patients but also the tem-
poral complexities of the inflammatory response, and if
certain inflammatory pathways are more affected by par-
ticular combinations of multitrauma and therefore more
appropriate to target therapeutically. For example, if
bone fracture combined with TBI is found to cause a
particularly significant increase in IL-1β expression in
the early stages post-injury, as found in mice [85], ther-
apies such as IL-1 receptor antagonists may prove to be
more effective in this form of TBI. However, if inflam-
matory responses in multitrauma patients involve gener-
alized hyperinflammation, therapies that target systemic
inflammation via neuronal inflammatory reflexes may
prove to be more appropriate interventions [91]. Fur-
thermore, the potential contribution of other path-
ways such as reactive oxygen species [16, 38], fat emboli
[36, 37], haemorrhagic shock [34, 60], and mobilized
mesenchymal stem cells [92, 93] to TBI pathobiology in
the patient with concomitant peripheral injuries are
possible but remain unknown (see Fig. 1).
Conclusions
TBI is a devastating condition that currently lacks a
treatment that improves patient outcomes. In light of
the many past failures in clinical trials in TBI, we must
now recognize and investigate factors that can impact
TBI pathophysiology, and ultimately patient outcomes, if
we are to one day improve the care of TBI sufferers.
Though not without limitations, many of the clinical
multitrauma/polytrauma studies discussed in this review
indicate that peripheral injuries may increase the risk of
mortality and functional deficits following TBI, particu-
larly when severe extracranial injuries are combined with
mild to moderate brain injury. In addition, several recent
animal studies have provided strong evidence that con-
comitant injuries may increase both peripheral and cen-
tral inflammatory responses and that structural and
functional deficits associated with TBI may be exacer-
bated in multiply injured animals. Taken together, the
findings of this review suggest that concomitant periph-
eral injuries are capable of modifying the outcomes and
pathobiology of TBI, in particular neuroinflammation,
and should be accounted for in future pre-clinical and
clinical studies.
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